相似文献
1
Equivalents in biotechnology patents.
Nat Biotechnol. 2003 Mar;21(3):329-31. doi: 10.1038/nbt0303-329.
2
Ownership at too high a price?
Nat Biotechnol. 2003 Sep;21(9):953. doi: 10.1038/nbt0903-953.
3
Napster case spills into biotech sector.
Nat Biotechnol. 2004 Sep;22(9):1185-6.
4
Biotechs sue Columbia over fourth Axel patent.
Nat Biotechnol. 2003 Sep;21(9):955-6. doi: 10.1038/nbt0903-955.
5
The importance of getting inventorship right.
Nat Biotechnol. 2006 Feb;24(2):153-4. doi: 10.1038/nbt0206-153.
6
Is the viability of the Lilly doctrine on the decline?
Nat Biotechnol. 2003 Aug;21(8):943-4. doi: 10.1038/nbt0803-943.
7
Determining the meaning of claim terms.
Nat Biotechnol. 2006 Jan;24(1):41-3. doi: 10.1038/nbt0106-41.
8
The 'Lilly doctrine' is viable and critical.
Nat Biotechnol. 2003 Oct;21(10):1131-2. doi: 10.1038/nbt1003-1131b.
9
US courts narrow patent exemptions.
Nat Biotechnol. 2003 Aug;21(8):834. doi: 10.1038/nbt0803-834.
10
The coming US patent opposition.
Nat Biotechnol. 2005 Feb;23(2):245-7. doi: 10.1038/nbt0205-245.
Zotero 插件